SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients

URN to cite this document:: urn:nbn:de:bvb:355-epub-305847
DOI to cite this document:: 10.5283/epub.30584

Schif, Birgit ; Lennerz, Jochen K. ; Kohler, Christian ; Bentink, Stefan ; Kreuz, Markus ; Melzner, Ingo ; Ritz, Olga ; Trümper, Lorenz ; Loeffler, Markus ; Spang, Rainer ; Möller, Peter

Preview

License: Creative Commons: Attribution 3.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 08 Aug 2014 13:07

Alternative links to fulltext:Pubmed

Details

Preview

Export bibliographical data

Abstract

Suppressor of cytokine signaling 1 (SOCS1) is frequently mutated in primary mediastinal and diffuse large B-cell lymphomas (DLBCL). Currently, the prognostic relevance of these mutations in DLBCL is unknown. To evaluate the value of the SOCS1 mutation status as a prognostic biomarker in DLBCL patients, we performed full-length SOCS1 sequencing in tumors of 154 comprehensively characterized DLBCL ...